Literature DB >> 1630914

Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

D Ronen1, Y Teitz, N Goldfinger, V Rotter.   

Abstract

To facilitate the purification of wild type p53 protein, we established a recombinant p53 vaccinia viral expression system. Using this efficient eukaryotic expression vector, we found that the expressed p53 proteins retained their specific structural characteristics. A comparison between wild type and mutant p53 proteins showed the conservation of the typical subcellular localization and the expression of specific antigenic determinants. Furthermore, wild type p53 exhibited a typical binding with large T antigen, whereas no binding was detected with mutant p53. Both wild type and mutant p53 proteins were highly stable and constituted 5-7% of total protein expressed in the infected cells. These expression recombinant viruses offer a simple, valuable system for the purification of wild type and mutant p53 proteins that are expressed abundantly in eukaryotic cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1630914      PMCID: PMC312500          DOI: 10.1093/nar/20.13.3435

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  62 in total

1.  Involvement of wild-type p53 protein in the cell cycle requires nuclear localization.

Authors:  G Shaulsky; N Goldfinger; A Peled; V Rotter
Journal:  Cell Growth Differ       Date:  1991-12

2.  Involvement of wild-type p53 in pre-B-cell differentiation in vitro.

Authors:  G Shaulsky; N Goldfinger; A Peled; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

3.  Mutant p53 proteins bind DNA abnormally in vitro.

Authors:  S E Kern; K W Kinzler; S J Baker; J M Nigro; V Rotter; A J Levine; P Friedman; C Prives; B Vogelstein
Journal:  Oncogene       Date:  1991-01       Impact factor: 9.867

4.  Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene.

Authors:  E May; J R Jenkins; P May
Journal:  Oncogene       Date:  1991-08       Impact factor: 9.867

5.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

6.  Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells.

Authors:  D Wilcock; D P Lane
Journal:  Nature       Date:  1991-01-31       Impact factor: 49.962

7.  p53 mutations in colorectal cancer.

Authors:  N R Rodrigues; A Rowan; M E Smith; I B Kerr; W F Bodmer; J V Gannon; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

8.  Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.

Authors:  G Shaulsky; N Goldfinger; V Rotter
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

9.  Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate.

Authors:  Y M Chen; P L Chen; N Arnaiz; D Goodrich; W H Lee
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

Review 10.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

View more
  3 in total

1.  Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form.

Authors:  R Wolkowicz; A Peled; N B Elkind; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

Review 2.  Prospects for the therapeutic use of anticancer vaccines.

Authors:  R S Chamberlain
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

3.  Selective repression of v-abl-encoded protein by N-methylisatin-beta-4',4'-diethylthiosemicarbazone and N-allylisatin-beta-4',4'-diallylthiosemicarbazone.

Authors:  Y Teitz; E Ladizensky; N Barko; E Burstein
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.